Equities

Pro Medicus Ltd

Pro Medicus Ltd

Actions
  • Price (USD)124.22
  • Today's Change0.00 / 0.00%
  • Shares traded15.00
  • 1 Year change+134.38%
  • Beta--
Data delayed at least 15 minutes, as of Nov 07 2024 20:46 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Pro Medicus Ltd grew revenues 30.63% from 127.33m to 166.33m while net income improved 36.52% from 60.65m to 82.79m.
Gross margin99.82%
Net profit margin49.78%
Operating margin70.04%
Return on assets36.03%
Return on equity50.72%
Return on investment42.01%
More ▼

Cash flow in AUDView more

In 2024, cash reserves at Pro Medicus Ltd fell by 31.19m. However, the company earned 81.98m from its operations for a Cash Flow Margin of 49.29%. In addition the company used 73.28m on investing activities and also paid 39.84m in financing cash flows.
Cash flow per share0.8725
Price/Cash flow per share233.47
Book value per share1.80
Tangible book value per share1.61
More ▼

Balance sheet in AUDView more

Pro Medicus Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 1.09%.
Current ratio5.98
Quick ratio5.98
Total debt/total equity0.011
Total debt/total capital0.0109
More ▼

Growth rates in AUD

SmartText is unavailable
Div yield(5 year avg)0.35%
Div growth rate (5 year)37.97%
Payout ratio (TTM)27.75%
EPS growth(5 years)34.00
EPS (TTM) vs
TTM 1 year ago
36.38
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.